Incyte Corp traded at $77.67 this Friday July 1st, increasing $1.70 or 2.24 percent since the previous trading session. Looking back, over the last four weeks, Incyte Corp gained 4.07 percent. Over the last 12 months, its price fell by 7.07 percent. Looking ahead, we forecast Incyte Corp to be priced at 76.09 by the end of this quarter and at 70.11 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
77.67
Daily Change
2.24%
Yearly
-7.07%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Acadia Pharmaceuticals 14.37 0.28 1.99% -40.86%
Agenus 1.96 0.02 1.03% -64.49%
Agios Pharmaceuticals 23.36 1.19 5.37% -58.08%
Alnylam Pharmaceuticals 148.25 2.40 1.65% -13.52%
Amgen 245.55 2.25 0.92% -1.27%
BioCryst Pharmaceuticals 10.84 0.26 2.46% -34.22%
Biogen 210.63 6.69 3.28% -39.60%
Bluebird Bio 4.28 0.14 3.38% -86.36%
BioMarin Pharmaceutical 84.98 2.11 2.55% -0.57%
Bristol-Myers Squibb 76.84 -0.16 -0.21% 14.77%
ChemoCentryx 26.76 1.98 7.99% 103.03%
Clovis Oncology 2.85 1.05 58.33% -49.91%
CTI Biopharma 6.08 0.11 1.84% 133.85%
Exelixis 21.57 0.75 3.60% 18.13%
Gilead Sciences 62.36 0.55 0.89% -10.01%
Intercept Pharmaceuticals 14.13 0.32 2.32% -29.31%
Idera Pharmaceuticals 0.44 -0.02 -4.58% -62.56%
Incyte Corp 77.67 1.70 2.24% -7.07%
Ionis Pharmaceuticals 38.06 1.04 2.81% -4.66%
Eli Lilly 324.71 0.48 0.15% 38.79%
MacroGenics 3.05 0.10 3.39% -89.37%
Merck & Co 92.42 1.25 1.37% 17.58%
Moderna Inc 149.95 7.10 4.97% -36.00%
Mirati Therapeutics 71.18 4.05 6.03% -57.53%
Neurocrine Biosciences 99.25 1.77 1.82% 0.65%
Nektar Therapeutics 3.75 -0.05 -1.32% -78.08%
Lumos Pharma Inc. 7.69 -0.01 -0.13% -24.61%
Novartis 80.33 -0.52 -0.64% -4.96%
Novartis 84.36 -0.17 -0.20% -8.28%
Puma Biotechnology 2.78 -0.07 -2.46% -68.48%
Pfizer 52.31 -0.12 -0.23% 31.66%
PTC Therapeutics 41.85 1.79 4.47% -2.88%
Ultragenyx Pharmaceutical 62.65 2.99 5.01% -33.50%
Regeneron Pharmaceuticals 595.40 4.27 0.72% 2.01%
Seattle Genetics 180.11 3.17 1.79% 14.52%
Sarepta Therapeutics 75.71 0.75 1.00% 0.62%
Vertex Pharmaceuticals 287.32 5.53 1.96% 43.27%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%
US500 3825 39.95 1.06% -12.11%
USNDX 11586 81.96 0.71% -21.33%

Incyte Corp
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.